Hawkins earnings release, October 26, 2026

Hawkins Inc (HWKN) · Form 8-K, Item 2.02 · Filed · SEC filing

Hawkins, Inc. Reports

Second Quarter Fiscal 2027 Results

Roseville, Minn., October 26, 2026 – Hawkins, Inc. (Nasdaq: HWKN) today announced results for its second quarter of fiscal 2027, the three months ended September 27, 2026.

Second Quarter Fiscal Year 2027 Highlights:

(All comparisons are to the second quarter of fiscal 2026 unless otherwise noted.)

• Record second quarter revenue of $313.8 million, with growth of 12%, driven by increased sales across all segments, including Water Treatment segment growth of 16%, Food & Health Sciences segment growth of 5%, and Industrial Solutions segment growth of 10%.

• Record second quarter gross profit of $76.6 million, an increase of 13%.

• Record second quarter diluted earnings per share ("EPS") of $1.34 increased $0.25, or 23%.

• Record second quarter net income of $27.8 million increased 23%, with record trailing twelve-month net income of $85.8 million. Record Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“adjusted EBITDA”), a non-GAAP measure, of $59.1 million, a 16% increase. Record trailing twelve-month adjusted EBITDA of $188.0 million.

• Generated operating cash flow of $75.5 million, an increase of 6% for the six months ended September 27, 2026. Free cash flow, defined as net cash provided by operating activities less capital expenditures, increased 14% to $53.1 million compared to the same period in the prior year, which we allocated to repurchasing $18.6 million of stock, paying down $15.0 million of debt and paying $8.1 million in dividends.

• Closed our second acquisition of fiscal 2027 with the purchase of Dave Symonds & Associates, Inc., a blended phosphates for corrosion control and sequestration focused water distributor based in Florida.

• Subsequent to quarter end, we expanded into the Dallas–Fort Worth region, pairing our greenfield Water Treatment facility with the acquisition of Eagle Labs, Inc., a water treatment distributor with in-house manufacturing capabilities and expertise in coagulants and polymers.

Executive Commentary – Patrick H. Hawkins, Chief Executive Officer and President:

“Our record second-quarter results in revenue, gross profit, EPS, and adjusted EBITDA reflect the agility of our employees and the resilience of our business model,” said Patrick Hawkins, President and Chief Executive Officer. “Revenue grew 12% in the quarter, including organic growth of 11%, with all three segments growing and Water Treatment revenue up 16%, primarily driven by increased volumes. Gross profit grew 13%, again led by Water Treatment at 20%, driven by volume growth and higher per-unit dollar margins. That gross profit growth flowed through to the bottom line, with diluted EPS up 23% and record adjusted EBITDA of $59 million, up 16%.”

Mr. Hawkins continued, “We continue to generate strong cash flow. During the quarter, we repurchased $12 million of our stock, paid down $15 million of debt, and closed on the acquisition of Dave Symonds & Associates, a tuck-in that expands our Water Treatment customer reach in Florida. Our leverage ratio at the end of the second quarter was 1.22x adjusted EBITDA, down from 1.37x at the end of fiscal 2026 and 1.54x in the same quarter last year. Subsequent to quarter end, we closed on the acquisition of Eagle Labs, which adds two locations in the Dallas–Fort Worth region, continuing our expansion in Texas. We will continue to deliver on our strategy of investing in our higher-margin businesses, acquiring companies that are accretive to Hawkins, and serving the needs of our customers to the highest level possible.”

Mr. Hawkins concluded, “Looking forward we expect the second half trends to be consistent with what we saw in the first half, recognizing that SG&A in the second half of fiscal 2026 benefited from a non-recurring $6.2 million reduction in SG&A which will not recur in the second half of fiscal 2027.”

Second Quarter Financial Highlights:

NET INCOME

For the second quarter of fiscal 2027, we reported net income of $27.8 million, or $1.34 per diluted share, compared to net income for the second quarter of fiscal 2026 of $22.6 million, or $1.08 per diluted share.

REVENUE

Sales were $313.8 million for the second quarter of fiscal 2027, an increase of $33.4 million, or 12%, from sales of $280.4 million in the same period a year ago. All of our segments grew by 5% or more from the same period a year ago. Sales increased as a result of 11% organic sales growth and approximately $3.7 million of sales from acquired businesses.

Water Treatment segment sales increased $24.1 million, or 16%, to $175.0 million for the current quarter, from $150.9 million in the same period a year ago. Organic sales grew 14%, driven primarily by increased volumes, along with improved pricing on certain of our products. Growth was broad-based across our product lines and end markets, with the municipal end market particularly strong. Acquired businesses contributed approximately $3.7 million in additional sales.

Food & Health Sciences segment sales increased $3.8 million, or 5%, to $76.7 million for the current quarter, from $72.9 million in the same period a year ago. Sales dollars increased as a result of increased volumes of our nutrition, food ingredients, and pharmaceutical products, partially offset by decreased sales of our agricultural products.

Industrial Solutions segment sales increased $5.6 million, or 10%, to $62.2 million for the current quarter, from $56.6 million in the same period a year ago. Sales increased as a result of improved pricing and favorable product mix, which more than offset lower volumes.

GROSS PROFIT... (truncated)ased, and gross profit decreased, by $0.3 million. The $1.6 million year-over-year impact of the unfavorable LIFO reserve was partially offset by $1.3 million of refunds of previously paid tariffs, which were recorded as a reduction of cost of sales. The refunded tariffs related to products for which customer pricing had not been increased in response to tariffs. Gross profit was also pressured by higher fuel costs that were not fully recovered through freight charges billed to customers.

Gross profit for the Water Treatment segment increased $8.4 million, or 20%, to $51.7 million, or 30% of sales, for the current quarter, from $43.3 million, or 29% of sales, in the same period a year ago. During the current quarter, the LIFO reserve increased, and gross profit decreased, by $0.5 million. In the same period a year ago, the LIFO reserve decreased, and gross profit increased minimally. The $0.5 million year-over-year impact of the unfavorable LIFO reserve was more than offset by $1.2 million of refunds of previously paid tariffs, which were recorded as a reduction of cost of sales. The increase in gross profit was primarily driven by higher sales.

Gross profit for the Food & Health Sciences segment decreased $0.6 million, or 4%, to $14.9 million, or 19% of sales, for the current quarter, from $15.5 million, or 21% of sales, in the same period a year ago. During the current quarter, the LIFO reserve increased, and gross profit decreased, by $0.7 million. In the same period a year ago, the LIFO reserve increased, and gross profit decreased, by $0.2 million. Gross profit decreased as lower margins in our food and pharmaceutical products and the $0.5 million year-over-year impact of the unfavorable LIFO reserve more than offset the benefit of higher segment sales and improved margins in our nutrition and agriculture products.

Gross profit for the Industrial Solutions segment increased $1.1 million, or 12%, to $10.0 million, or 16% of sales, for the current quarter, from $8.9 million, or 16% of sales, in the same period a year ago. During the current quarter, the LIFO reserve increased, and gross profit decreased, by $0.7 million. In the same period a year ago, the LIFO reserve increased, and gross profit decreased, by $0.1 million. The benefit of higher sales and favorable product mix was partially offset by the $0.6 million year-over-year impact of the unfavorable LIFO reserve.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative (“SG&A”) expenses increased $1.0 million, or 3%, to $34.7 million, or 11% of sales, for the three months ended September 27, 2026, from $33.7 million, or 12% of sales, in the same period a year ago. This included $0.4 million due to added costs from the acquired businesses in our Water Treatment segment. SG&A expenses also increased due to increases in other variable costs, including variable pay and other personnel costs. These increases were partially offset by a $0.5 million decrease in non-qualified deferred compensation plan expense, as appreciation in the market value of plan investments was lower than in the same period a year ago. Deferred compensation plan expense is offset by a corresponding gain on plan investments recorded in other income (expense).

ADJUSTED EBITDA

Adjusted EBITDA, a non-GAAP financial measure, is an important performance indicator and a key compliance measure under the terms of our credit agreement. An explanation of the computation of adjusted EBITDA is presented below. Adjusted EBITDA for the three months ended September 27, 2026 was $59.1 million, an increase of $8.2 million, or 16%, from $50.9 million in the same period a year ago. In the third quarter of fiscal 2026, we revised our definition of adjusted EBITDA to exclude non-cash earnout related expense and income, in order to better reflect results from operations. Prior-year adjusted EBITDA has been recast in accordance with the current definition. As originally reported, adjusted EBITDA for the three months ended September 28, 2025 was $50.4 million, which included non-cash earnout related expense that is excluded under the current definition.

INCOME TAXES

Our effective income tax rate was 30% for the current quarter and 27% for the same period a year ago. The effective income tax rate for each period exceeded the U.S. federal statutory rate of 21%, primarily due to state income taxes on non-deductible expenses, including executive compensation and other permanent items. The increase in the effective income tax rate compared with prior-periods was primarily due to higher state income taxes and an increase in non-deductible items. The effective tax rate is impacted by projected levels of annual taxable income, permanent items, state taxes and discrete items, including tax effects of stock-based compensation. Our effective tax rate for the full year is expected to be approximately 25% to 27%.

Financial statements

Income Statement

Adjusted EBITDA (in thousands)

Three months ended – September 27, 2026Three months ended – September 28, 2025Six months ended – September 27, 2026Six months ended – September 28, 2025Trailing Twelve months ended – September 27, 2026
Net Income (GAAP)27,78122,59856,03551,77385,810
Interest expense, net2,6433,8325,4167,10111,822
Income tax expense11,7468,23120,81618,06230,546
Amortization of intangibles5,5035,52711,01910,34821,963
Depreciation expense8,7927,73517,22115,20533,266
Non-cash compensation expense1,9332,3754,1684,5878,154
Non-recurring acquisition expenses (1)14070203940501
Non-cash earnout related expense (income)5525351,087-1,048-4,042
Adjusted EBITDA59,09050,903115,965106,968188,020

Income Statement

Three months ended — (In thousands, except share and per-share data)

Three months ended – September 27, 2026Three months ended – September 28, 2025Six months ended – September 27, 2026Six months ended – September 28, 2025
Sales313,817280,434629,492573,706
Cost of sales-237,211-212,791-478,879-433,701
Gross profit76,60667,643150,613140,005
Selling, general and administrative expenses-34,700-33,703-70,035-64,732
Operating income41,90633,94080,57875,273
Interest expense, net-2,643-3,832-5,416-7,101
Other income2647211,6891,663
Income before income taxes39,52730,82976,85169,835
Income tax expense-11,746-8,231-20,816-18,062
Net income27,78122,59856,03551,773
Weighted average number of shares outstanding - basic20,710,22820,737,74320,743,85520,727,614
Weighted average number of shares outstanding - diluted20,783,04420,845,74420,827,21920,837,595
Basic earnings per share1.341.092.72.5
Diluted earnings per share1.341.082.692.48
Cash dividends declared per common share0.20.190.390.37

Income Statement

Water Treatment — (In thousands) (in thousands)

Three months ended September 27, 2026: – Water TreatmentThree months ended September 27, 2026: – Food & Health SciencesThree months ended September 27, 2026: – Industrial SolutionsThree months ended September 27, 2026: – Total
Sales174,96176,67962,177313,817
Cost of sales - materials-104,388-57,350-49,294-211,032
Cost of sales - operational overhead-18,824-4,432-2,923-26,179
Gross profit51,74914,8979,96076,606
Selling, general, and administrative expenses-23,477-7,941-3,282-34,700
Operating income28,2726,9566,67841,906
Three months ended September 28, 2025:Sales150,90872,91456,612280,434
Three months ended September 28, 2025:Cost of sales - materials-88,814-53,153-45,131-187,098
Three months ended September 28, 2025:Cost of sales - operational overhead-18,833-4,280-2,580-25,693
Three months ended September 28, 2025:Gross profit43,26115,4818,90167,643
Three months ended September 28, 2025:Selling, general, and administrative expenses-22,071-8,084-3,548-33,703
Three months ended September 28, 2025:Operating income21,1907,3975,35333,940
Six months ended September 27, 2026:Sales333,254173,929122,309629,492
Six months ended September 27, 2026:Cost of sales - materials-198,869-130,695-97,152-426,716
Six months ended September 27, 2026:Cost of sales - operational overhead-37,140-9,062-5,961-52,163
Six months ended September 27, 2026:Gross profit97,24534,17219,196150,613
Six months ended September 27, 2026:Selling, general, and administrative expenses-47,147-15,969-6,919-70,035
Six months ended September 27, 2026:Operating income50,09818,20312,27780,578
Six months ended September 28, 2025:Sales300,474162,091111,141573,706
Six months ended September 28, 2025:Cost of sales - materials-177,973-118,967-87,979-384,919
Six months ended September 28, 2025:Cost of sales - operational overhead-35,493-8,295-4,994-48,782
Six months ended September 28, 2025:Gross profit87,00834,82918,168140,005
Six months ended September 28, 2025:Selling, general, and administrative expenses-41,156-16,465-7,111-64,732
Six months ended September 28, 2025:Operating income45,85218,36411,05775,273

Balance Sheet

(In thousands, except share data)

September 27, 2026March 29, 2026
CURRENT ASSETS:Cash and cash equivalents7,1003,914
CURRENT ASSETS:Trade accounts receivables, net149,281139,796
CURRENT ASSETS:Inventories92,94778,199
CURRENT ASSETS:Prepaid expenses and other current assets7,7939,556
CURRENT ASSETS:Total current assets257,121231,465
CURRENT ASSETS:Property, plant, and equipment509,360489,662
CURRENT ASSETS:Less accumulated depreciation237,614223,406
CURRENT ASSETS:Net property, plant, and equipment271,746266,256
OTHER ASSETS:Right-of-use assets, net17,17016,840
OTHER ASSETS:Goodwill224,439223,042
OTHER ASSETS:Intangible assets, net224,455232,887
OTHER ASSETS:Deferred compensation plan asset15,64912,812
OTHER ASSETS:Other1,4722,988
OTHER ASSETS:Total other assets483,185488,569
OTHER ASSETS:Total assets1,012,052986,290
CURRENT LIABILITIES:Accounts payable — trade69,60959,835
CURRENT LIABILITIES:Accrued payroll and employee benefits15,74620,092
CURRENT LIABILITIES:Income tax payable5,02598
CURRENT LIABILITIES:Environmental remediation7,7007,700
CURRENT LIABILITIES:Other current liabilities14,67617,119

Cash Flow

Free Cash Flow Reconciliation (in thousands)

Six months ended – September 27, 2026Six months ended – September 28, 2025
Net cash provided by operating activities75,48871,031
Less: Purchases of property, plant & equipment-22,355-24,342
Free cash flow53,13346,689

Cash Flow

Six months ended — (In thousands) (in thousands)

Six months ended – September 27, 2026Six months ended – September 28, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:Net income56,03551,773
Reconciliation to cash flows:Depreciation and amortization28,24025,553
Reconciliation to cash flows:Change in fair value of earnout liabilities1,087-1,048
Reconciliation to cash flows:Operating leases2,1211,881
Reconciliation to cash flows:Gain on deferred compensation assets-1,689-1,664
Reconciliation to cash flows:Deferred income taxes1,131
Reconciliation to cash flows:Stock compensation expense4,1684,587
Reconciliation to cash flows:Other, net-608
Changes in operating accounts providing (using) cash:Trade receivables-9,9495,140
Changes in operating accounts providing (using) cash:Inventories-14,550-5,196
Changes in operating accounts providing (using) cash:Accounts payable9,676-11,013
Changes in operating accounts providing (using) cash:Accrued liabilities-6,320-4,209
Changes in operating accounts providing (using) cash:Lease liabilities-2,376-1,897
Changes in operating accounts providing (using) cash:Income taxes5,1734,082
Changes in operating accounts providing (using) cash:Other, net2,8013,034
Changes in operating accounts providing (using) cash:Net cash provided by operating activities75,48871,031
CASH FLOWS FROM INVESTING ACTIVITIES:Purchases of property, plant, and equipment-22,355-24,342
CASH FLOWS FROM INVESTING ACTIVITIES:Acquisitions-5,200-162,508
CASH FLOWS FROM INVESTING ACTIVITIES:Proceeds from asset disposals5171,037
CASH FLOWS FROM INVESTING ACTIVITIES:Net cash used in investing activities-27,038-185,813
CASH FLOWS FROM FINANCING ACTIVITIES:Cash dividends declared and paid-8,136-7,723
CASH FLOWS FROM FINANCING ACTIVITIES:New shares issued1,6811,609
CASH FLOWS FROM FINANCING ACTIVITIES:Payroll taxes paid in exchange for shares withheld-5,143-3,028
CASH FLOWS FROM FINANCING ACTIVITIES:Shares repurchased-18,646
CASH FLOWS FROM FINANCING ACTIVITIES:Payments on senior secured revolving loan-20,000-40,000
CASH FLOWS FROM FINANCING ACTIVITIES:Payments for debt issuance costs-764
CASH FLOWS FROM FINANCING ACTIVITIES:Borrowings on senior secured revolving loan5,000170,000
CASH FLOWS FROM FINANCING ACTIVITIES:Other-20
CASH FLOWS FROM FINANCING ACTIVITIES:Net cash (used in) provided by financing activities-45,264120,094
CASH FLOWS FROM FINANCING ACTIVITIES:NET INCREASE IN CASH AND CASH EQUIVALENTS3,1865,312
CASH FLOWS FROM FINANCING ACTIVITIES:CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD3,9145,103
CASH FLOWS FROM FINANCING ACTIVITIES:CASH AND CASH EQUIVALENTS, END OF PERIOD7,10010,415
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATIONCash paid for income taxes14,51213,980
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATIONCash paid for interest5,4807,182
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATIONNoncash investing activities - capital expenditures in accounts payable2,2731,568

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.